This Special Issue will focus on the latest research in brain targeted drug delivery. Submit your manuscript by June 30, 2024.
The prevalence of central nervous diseases poses significant challenges to society, particularly with the global aging population. While various potential chemical agents, antibodies, and genes have been developed for the treatment of these diseases, the effectiveness of these treatments is greatly hindered by the presence of the blood-brain barrier.
We are pleased to announce that the American Chemical Society journal Bioconjugate Chemistry will publish a Special Issue titled “Brain Targeted Drug Delivery.” With this issue we aim to bring together researchers from different disciplines to share their knowledge and expertise in brain targeted drug delivery.
We welcome topics including, but not limited to:
- Novel approaches to overcome the blood-brain barrier
- Intranasal delivery methods for efficient drug transport to the brain
- Innovative drug delivery strategies for a variety of central nervous system diseases
- Emerging combinations of therapies for the treatment of glioma and Alzheimer’s disease
Guest Editors
Dr. Huile Gao
Sichuan University, China
Dr. Zhiqing Pang
Fudan University, China
Dr. Yang Liu
Sun Yat-Sen University, China
Dr. Jia Li
Macquarie University, Australia
How to Submit
- Log in to the ACS Paragon Plus submission site.
- Choose Bioconjugate Chemistry as your journal.
- Select your manuscript type.
- Under “Special Issue Selection” choose “Brain Targeted Drug Delivery.”
Please see Bioconjugate Chemistry’s Author Guidelines for more information on submission requirements. The deadline for submissions is June 30, 2024.
Open Access
There are diverse open access options for publications in American Chemical Society journals. Please visit our Open Science Resource Center for more information.
Want More From This Journal?
Stay Connected
Sign up now for email updates on future calls for papers, the latest issues, and other content from Bioconjugate Chemistry.